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ABSTRACT A major obstacle to 3-dimensional tissue
engineering is incorporation of a functional vascular
supply to support the expanding new tissue. This is
overcome in an in vivo intrinsic vascularization model
where an arteriovenous loop (AVL) is placed in a
noncollapsible space protected by a polycarbonate
chamber. Vascular development and hypoxia were ex-
amined from 3 days to 112 days by vascular casting,
morphometric, and morphological techniques to un-
derstand the model’s vascular growth and remodeling
parameters for tissue engineering purposes. At 3 days a
fibrin exudate surrounded the AVL, providing a scaf-
fold to migrating inflammatory, endothelial, and mes-
enchymal cells. Capillaries formed between 3 and 7
days. Hypoxia and cell proliferation were maximal at 7
days, followed by a peak in percent vascular volume at
10 days (23.203.14% compared with 3.592.68% at 3
days, P<0.001). Maximal apoptosis was observed at 112
days. The protected space and spontaneous microcir-
culatory development in this model suggest it would be
applicable for in vivo tissue engineering. A temporal
window in a period of intense angiogenesis at 7 to 10
days is optimal for exogenous cell seeding and survival
in the chamber, potentially enabling specific tissue
outcomes to be achieved.—Lokmic, Z., Stillaert, F.,
Morrison, W. A., Thompson, E. W., Mitchell, G. M. An
arteriovenous loop in a protected space generates a
permanent, highly vascular, tissue-engineered con-
struct. FASEB J. 21, 511–522 (2007)
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a chronic shortage of living and cadaveric donor
organs and an increase in the number of patients
waiting for organ transplants (1) have instigated a
search for alternative sources of functional tissues and
organs. Recent advances in tissue-engineered products
used clinically include cartilage (2), skin (3), urethra
(4), and blood vessels 5 mm in diameter (5). The
success of these products in vivo is due mainly to their
small 2-dimensional volume or avascular nature, which
permits them to survive in vivo implantation. Subse-
quent ingrowth of capillaries from the recipient site
vessels nourishes these constructs. This has been
termed extrinsic vascularization. Although moderately
successful, this technique relies on using minute con-
struct combinations of cells and extracellular matrix
(ECM) that must survive on diffusion prior to ingrowth
of capillaries. Permanent, large, independent con-
structs grown under these conditions are yet to be
created.
An alternative to extrinsic vascularization is an intrin-
sic approach. Intrinsic vascularization is utilized in a
novel tissue-engineering construct in which a macrovas-
cular arteriovenous shunt loop (AVL) is enclosed in an
isolated protected space created by a polycarbonate
chamber. Spontaneous new tissue growth without the
addition of extracellular matrices or growth factors has
been observed in this construct (6).
The advantages of the AVL model for tissue engi-
neering purposes include the following: 1) the rigid
noncollapsible chamber walls create a large permanent
space in which new tissue and vasculature can expand;
the chamber allows rapid localization, manipulation,
and retrieval of the construct at any time, and chamber
shape and size can be varied according to tissue re-
quirements; and 2) as the contents of the chamber are
contained, timed delivery of specific cell populations,
growth factors, matrices, or differentiation agents could
ultimately direct specific tissue or organoid outcomes
in this model.
Although the AVL chamber model possesses a num-
ber of highly desirable tissue engineering properties,
the characteristics of its microcirculatory growth, re-
modeling, and permanency are unknown.
Angiogenesis, the formation of new capillaries, arte-
rioles, and venules from endothelial cells (ECs),
smooth muscle cells (SMCs), and/or pericytes, is nec-
essary for the formation of a microcirculatory network
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(7) in viable tissue-engineered constructs. The role of
blood-borne endothelial precursor cells in the forma-
tion of tissue-engineered microcirculatory networks is
so far undetermined, but it is probable that this mech-
anism plays some role in tissue-engineered microcircu-
latory development (8, 9).
In vitro creation of engineered microcirculatory net-
works has had some success (10–12), but there are
significant design restrictions in expanding these con-
structs for large 3-dimensional tissue engineering re-
quired in clinical settings (13).
Although many in vivo tissue engineering studies
have reported extrinsic capillary growth into their
constructs, usually in response to specific angiogenic
growth factor administration (14–16) and quantitation
of vascularity at a single short-term time point (17, 18),
few studies, with the exception of Koike et al. (19), have
included a quantitative temporal study of vascular
development and remodeling in an in vivo tissue engi-
neering construct.
In this study, the main aim was to determine the
extent, growth characteristics, and remodeling of the
naturally occurring, intrinsically generated blood vessel
network of AVL constructs grown in polycarbonate
chambers. Understanding this phenomenon is crucial
to further exploitation of this model for tissue engi-
neering, especially for the targeted delivery of cells to
maximize their survival.
Blood vessel development in this engineered micro-
circulation was assessed over a 112 day (16 wk) time
frame, histologically, immunohistochemically, and by
transmission electron microscopy (TEM), to identify
cells initially invading the chamber and giving rise to a
new microcirculatory bed. Vascular casting, hy-
poxyprobe-1 labeling, proliferative and apoptotic cell
studies, and morphometry were then employed to
characterize vascular growth and remodeling.
MATERIALS AND METHODS
Animals
Six male Sprague-Dawley rats (ARC, Perth, Western Australia)
weighing between 280 and 320 g were used per time point
group (3, 7, 10, 14, 21, 28, 42, 56, and 112 days). Another two
rats were included in the 3, 7, 10, and 14 day groups for
vascular casting and two additional rats at the 7 day time point
were used for TEM. All experimental and medical procedures
were approved by the Animal Ethics Committee of St. Vin-
cent’s Hospital (34/02), Melbourne, Australia, and were
conducted in accordance with the Australian National Health
and Medical Research Council guidelines for the care and
maintenance of animals.
Creation of the AVL chamber model and harvest of the in
vivo engineered AVL construct
Rats were anesthetized with intraperitoneal (i.p.) phenobar-
bitone (30 mg/kg). Under sterile conditions the femoral
vessels of both legs were exposed between the inguinal
ligaments proximally and the bifurcation of the saphenous
and popliteal vessels distally. An 11 mm vein graft was
dissected from the left femoral vein and placed in sterile
heparinized saline. The right femoris artery and vein were
exposed, the profunda femurus artery and vein tied, and the
right superior epigastric artery and vein were dissected and
ligated 10 mm from their femoral vessel origin. The right
femoral artery and vein were cut distal to the epigastric
branches and the vein graft was interposed with microanas-
tomoses to create an AVL. The base of a sterile polycarbonate
chamber (Fig. 1A) (Department of Chemical and Biomolec-
ular Engineering, University of Melbourne, Australia) was
placed under the AVL (Fig. 1B) and sutured through open-
ings in the base into the underlying muscle fascia. The ligated
right superficial epigastric artery and vein were used to
anchor the AVL to the chamber as they were caught at the
edges of the chamber when the lid was closed over the base.
The opposed edges of the wounds were sutured together and
the animals were resuscitated.
Three, 7, 10, 14, 21, 28, 42, 56, or 112 days after chamber
implantation, the rats were anesthetized with phenobarbitone
(30 mg/kg), then the chamber tissue was harvested once the
artery and vein of the AVL were checked for patency.
Constructs were removed by tying off the AVL vessels 5 mm
proximal to the chamber entrance. After weighing and vol-
ume displacement measurements (20), the tissue was immer-
sion fixed in 4% paraformaldehyde (PFA), cut into 1 mm-
thick vertical slices, and processed for routine histology and
immunohistochemistry. Animals were euthanized by i.p. in-
jection of Lethobarb® (200 mg/kg, Virbac, Peakhurst, Aus-
tralia).
Identification of cellular populations invading the chamber
constructs
Paraffin-embedded 3 m-thick sections were cut from all
blocks at every time point and stained with hematoxylin and
eosin, toluidine blue, and Mason’s trichrome to examine the
overall tissue and vessel morphology within the construct.
To identify the cell phenotypes that first invade the fibrin
matrix, the following antibodies were used: anti-c-kit (c-19;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), Thy-1
(PharMingen International, San Diego, CA, USA), VEGFR-2
[also known as Flk-1 (AF 644, R&D Systems Minneapolis, MN,
USA)], -smooth muscle actin (-SMA), desmin (clone D33),
both purchased from Dakocytomation, Carpinteria, CA, USA,
and a macrophage marker, ED-1 (MCA341, Serotec, Oxford,
UK). Tissue sections were dewaxed and treated in 0.1 M citric
acid where required (c-kit, desmin). The sections were then
washed in PBS, pH 7.5, and treated with 3% H2O2 in
methanol for 10 min to block endogenous peroxidase. After
another wash in PBS, the sections were incubated for 20 min
in 10% goat (for -SMA, Thy-1, ED-1, and desmin) or rabbit
serum (for c-kit and VEGFR-2), followed by an overnight
incubation in primary antibody at 4°C at dilutions of: c-kit,
1:100; Thy-1, and ED-1, 1:1000; and desmin, 1:250. -SMA was
used at 1:400 dilution for 1 h at room temperature. The
primary antibody was detected using secondary antibodies:
biotinylated goat anti-mouse (for -SMA, ED-1, desmin,
and Thy-1) or goat anti-rabbit (for VEGFR-2) at 1:400
dilution and rabbit anti-goat horseradish peroxidase
(HRP) antibody (for c-kit) at 1:200 for 30 min at room
temperature. All secondary antibodies were purchased
from Dakocytomation. The biotinylated complexes were
detected using streptavidin-HRP (1:400; Dakocytomation)
and visualized with 33-diaminobenzidine (3,3 -
diaminobenzidine) (Dakocytomation). The negative con-
trols included substitution of a primary antibody with a
corresponding serum isotype.
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Transmission electron microscopy
Two rats with 7 day AVL chambers were anesthetized, the
abdominal cavity was opened, and heparin (300 U/kg) was
injected into the vena cava 5 min before cannulation of the
femoral artery. The construct was perfused with sodium cacody-
late buffer, pH 7.4 (37°C, at 100 mmHg) for 5 min, followed by
Karnovsky’s fixative (21). The construct was removed, cut into 1
mm-thick slices, placed in Karnovsky’s fixative overnight at 4°C,
followed by sodium cacodylate buffer overnight. Tissue slices
were further cut into 1 mm  2 mm tissue blocks (the position
around the AVL noted) and transferred into 2% osmium
tetroxide for 1 h, followed by distilled water washes and 2%
uranyl acetate in 70% acetone solution for 20 min prior to
dehydration through graded acetone and routine processing
into Spurr’s resin and polymerization. The resin-embedded
tissue was cut into 1 m sections and stained in 1% toluidine
blue. Suitable tissue blocks determined from light microscopic
examination were cut at 70–90 nm, then stained in 2% uranyl
acetate and Reynold’s lead/citrate solution. The sections were
viewed and photographed on a SIEMENS 102 electron micro-
scope at 60 KV.
Vascular casting
To macroscopically visualize AVL blood vessel development,
two additional rats per group at 3, 7, 10, and 14 days were
surgically prepared as for TEM and the constructs were
perfused with PBS (37°C, at 100 mmHg), followed by 4% PFA
(37°C) for 5 min. Resin (Mercox Kit, Ladd Research, Burl-
ington, VT, USA) was prepared per the manufacturer’s
instructions and infused through the same cannula until the
onset of polymerization. The construct was then removed and
Figure 1. A–D) Macroscopic views of chamber construct. A) Polycarbonate chamber base (B) and chamber lid (L), B) The AVL
positioned on the chamber base (B) prior to closing the chamber lid. A, femoral artery; VG, vein graft, V, femoral vein
components of the AVL. C) The chamber lid removed from a 3 day construct. Note the large amount of fibrin (F) covering the
AVL. Arrow indicates where the femoral artery and vein enter and leave the construct. D) A 112 day construct. A flap of healthy
tissue (T) covers the AVL, which is obscured. The femoral artery (A) and vein (V) entering and leaving the construct are visible.
E–H) AVL histology. E) Femoral artery in a 7 day construct. Scale bar  100 m. F) Femoral vein wall: medial SMCs have
disappeared, while the endothelial surface has a “piled up” appearance (large arrow). Large mesenchymal cells are evident in
the wall (arrowhead). Similar cells appear to be forming capillaries (asterisk), one of which is seen connecting to the vein lumen
(double arrow). Scale bar  20 m. G) The vein graft wall at 3 days. Arrow indicates luminal surface without endothelium.
Inflammatory cells (arrowhead) are evident in the surrounding fibrin. Scale bar 100 m. H) Endothelial coverage (arrow) on
the luminal surface of the vein graft at 7 days. Note the relatively acellular nature of the graft wall (asterisk). Scale bar  20 m.
I, J) Weight and volume of constructs to 112 days. I) The mean weight (g) (sd) of all constructs at each harvest time point..
J) The mean displacement volume (ml) (sd) of all constructs at each harvest time point.
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immersed in hot water (50°C) for 1 h to complete resin
curing. The surrounding tissue was removed by maceration in
alternating rinses of 5% potassium hydroxide and distilled
water (22).
Hypoxia studies
Two animals per group (3–28 days) were injected with 100
mg/kg of pimonidazole hydrochloride (hypoxyprobe-1, Hy-
poxyprobe™, Natural Pharmacia International, Inc., Bel-
mont, MA, USA) via the tail vein, as described previously
(23). A sample of liver tissue was collected as a positive
control. Negative control tissue consisted of liver and con-
struct tissues from hypoxyprobe-1-free animals. The negative
control for the immunohistochemistry consisted of omission
of a primary antibody from the reaction.
Proliferation studies
To detect proliferating cells, sections were stained with Ki67
(24), viewed under 40 magnification, and the image was
captured via a digital video camera (JVC, TK C1480E) at-
tached to the microscope. The entire tissue area was outlined
and the area was measured. A series of fields within that area
was then randomly and systematically sampled so that 5% of
total area of the tissue was counted using an electronic
stepping stage (H128, Prior Scientific, Rockland, USA) and
the Computer Assisted Stereological Toolbox (CAST System,
Olympus, Denmark), then expressed as mean number of
proliferating cells/mm2  sem. Rat intestine was used as the
positive control tissue.
TUNEL assay
Apoptotic cells in paraffin sections were detected as previ-
ously reported (25) and counted as described for proliferat-
ing cells. Rat lymph node was used as positive control tissue.
Hemosiderin-filled macrophages (26) were also TUNEL-pos-
itive; however, their staining pattern was vacuole-like, reflect-
ing the remnant phagocytosed DNA. These cells were easily
distinguished from other apoptotic cells due to the refractive
nature of hemosiderin and were excluded from the apoptotic
cell count.
Immunohistochemical demonstration of blood vessels and
morphometric determination of tissue components in AVL
constructs
Construct tissue sections were stained immunohistochemi-
cally with Bandeiraea Simplicifolia lectin (Vector Laboratories,
Burlingame, CA, USA) (23) to identify blood vessels. The
negative control consisted of the omission of the B. Simplici-
folia lectin from the reaction. To determine the percent
volume density of tissue components, stained sections were
viewed under20 magnification with a test grid eyepiece lens
placed over the sections. A random microscopic field was
selected as a starting point and every fifth field was counted.
Tissue categories counted were the AVL, fibrin matrix, con-
nective tissue, and blood vessel components of the constructs.
To determine percent volume of a tissue component, the
number of points counted for the individual component was
divided by the total number of points counted per section
and expressed as a percentage (27).
The vascular volume density within the new connective
tissue compartment was determined by counting the number
of points falling over a vessel (other than the AVL) divided by
the sum of points falling on new blood vessels and connective
tissue. This figure was then expressed as a percentage. Mor-
phometric counts were made independently by two blinded
observers (Z.L. and G.M.) and checked so that no more than
a 10% difference existed between counts from the two
observers.
Statistical analysis
The data for weight and volume were reported as mean sd.
For vascular morphometric studies, as well as the cellular
proliferation and apoptosis analysis, results were reported as
mean  sem for the total number of observations. Statistical
comparison between the groups was performed using one-
way ANOVA and the Bonferroni multiple comparisons test.
The results were considered statistically significant if
P 	 0.05.
RESULTS
Macroscopic appearance of the construct and AVL
patency
At 3 days, the major portion of the new construct tissue
was a fibrin clot surrounding the AVL (Fig. 1C) while at
subsequent time points a well-vascularized tissue flap
surrounded the AVL (Fig. 1D).
Only three chambers demonstrated an occluded
AVL when tested surgically (one specimen at 28, 56,
and 112 days) and were excluded from the study.
Histologically, 13 chambers demonstrated partial occlu-
sion of the AVL by thrombus (24.5% of all chambers)
and another 8 (15.1% of total) demonstrated complete
occlusion. Partial and complete occlusions were evenly
spread throughout the groups, with the majority at the
vein graft-femoral vein anastomosis. All occlusions be-
came revascularized and the tissue around the oc-
cluded vessels appeared healthy, as did all tissue
throughout the chamber constructs.
AVL histology
The artery wall of the AVL maintained a normal
muscular artery structure (Fig. 1E), although some
medial SMC loss occurred in the first few weeks.
The femoral vein was significantly altered at 7–10
days, with the appearance of new capillaries within the
wall and connecting to the lumen (Fig. 1F). SMC loss
occurred in the vein media and large numbers of cells
were observed migrating through the vein wall. The
endothelial layer was difficult to recognize as much of it
was “thickened” or had a piled-up appearance due to a
massive influx of cells, many of them inflammatory cells
(Fig. 1F).
The vein graft demonstrated loss of ECs and many
SMCs at 3 days (Fig. 1G). At later times endothelium
covered the graft luminal surface, while the graft media
was largely devoid of SMCs throughout the study period
(Fig. 1H). Cells migrating through the graft wall were
noted. Confined areas of thin neointimal hyperplasia
developed in the vein graft wall near its anastomosis
with the artery, from 14 days.
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Tissue weight and volume displacement analysis
The heaviest constructs were observed at 7
(0.3740.100 g) and 10 days (0.3490.068 g) (Fig. 1I).
The highest mean volume was observed at 7 days
(0.3300.102 ml) and 10 days (0.3160.069 ml) (Fig.
1J). After day 10, the weight and volume decreased
slightly, then stabilized after day 14.
Characterization of tissue growth and identification
of cell types
At 3 days a large fibrin clot had exuded from the AVL
and filled most of the chamber (Fig. 2A, B). No
collagen was observed around the AVL. Inflammatory
cells (neutrophils and ED-1-positive macrophages)
were seen migrating through the fibrin. Spindle-shaped
cells, the majority being -SMA-positive myofibroblasts,
were also observed in the fibrin around the AVL vein
(Fig. 3B). A few larger spindle-shaped cells were
VEGFR-2-positive (Fig. 4B, also observed at 7 days; Fig.
4D). Thy-1- and c-kit-positive cells were rarely seen in
the fibrin matrix.
By day 7 (Fig. 2C, D) the fibrin matrix around the
AVL was partially replaced by newly formed vascular-
ized connective tissue. Tissue development varied, but
was always more extensive adjacent to the femoral vein
of the AVL. Masson’s trichrome staining demonstrated
newly synthesized collagen replacing the fibrin. The
maturing vascularized connective tissue zone was de-
posited directly adjacent to the AVL, while a hemor-
rhagic proliferative zone lay sandwiched between the
Figure 2. a-h. Toluidine blue staining of vertical sections through AVL constructs. A, B) At 3 days, the AVL surrounded by fibrin
matrix (F). B) Inflammatory and mesenchymal cells (arrow) begin to migrate into the fibrin. (asterisk: AVL wall). C) At 7 days,
two cross sections through the AVL, now surrounded by a cuff of new connective tissue (asterisks) and fibrin (F). D) At 7 days,
the AVL (asterisk) surrounded by maturing connective tissue (M). Further from the AVL is the proliferative zone (P), including
new capillaries (arrow) migrating into the fibrin (F). E) At 14 days, the AVL is surrounded by a wide cuff of mature vascularized
connective tissue (M). The proliferative zone (P) and fibrin matrix (F) are reduced in width. F) Mature connective tissue (M)
at 14 days: arrow indicates arteriole; asterisk indicates venule. G) At 28 days, the AVL is covered by mature vascularized
connective tissue (M). No fibrin is evident. H) Mature tissue: arrows, blood vessels. Scale bars: A, C, E, G)  500 m; B, D, G,
H)  50 m. I–L) Resin casts of the AVL at day 10 (I, J) and day 14 (K, L). No capillaries or arterioles sprout from the vein graft
(VG) (I, K). Capillaries sprout (arrows) from the femoral vein (V) at 10 days (I, J). Occasional arterioles (thick arrows) branch
from the femoral artery (A) at day 10 (I) but were far more numerous at day 14 (K, L). Scale bars, I–L  2 mm.
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new connective tissue and the remaining fibrin matrix
(Fig. 2D). The immature, leaky capillaries of the prolif-
erative zone, which frequently demonstrated a discon-
tinuous endothelial lining, allowed blood to leak into
the surrounding fibrin, giving this zone a hemorrhagic
appearance that persisted to 28 days. Numerous inflam-
matory cells, -SMA-positive (Fig. 3C) and desmin-
positive cells (Fig. 3H) in the interstitium, and VEGFR-
2-positive capillaries (Fig. 4C) were observed in the
proliferative zone. Consistent with hemorrhage in the
construct was the accumulation of hemosiderin-filled
macrophages from 14 days.
The first arterioles were generally observed at 7–10
days (Fig. 3D). -SMA-positive and desmin-positive cells
(Fig. 3D, I, J) were observed in arteriole and capillary
walls. Definitive venules appeared at 14–21 days (Fig.
3E). Arterioles and venules persisted to 112 days (Fig.
3F, K).
As the fibrin matrix was gradually replaced by the
new microcirculation and connective tissue (Fig. 2E–
H), cell populations throughout the construct also
changed. Between 21 and 112 days, the numbers of
desmin- and -SMA-positive cells was markedly reduced
in the interstitial connective tissue, and reduced stain-
ing intensity was noted in blood vessel walls (Fig. 3F, K).
VEGFR-2 staining was maximal at 10 days (Fig. 4E) in
new vessel sprouts and largely confined to the prolifer-
ative zone. Weak VEGFR-2 labeling was observed at 14
days and was undetectable from 21 days onward (Fig.
4F). These changes occurred concurrently with a gen-
eral reduction in cellularity in the connective tissue.
Vascular casting
Three day AVL constructs demonstrated no capillary
sprouting when examined under a dissecting micro-
Figure 3. -SMC and desmin labeling in AVL constructs. A) Negative control tissue from a 10 day construct. No -SMA labeling
is evident. Scale bar  50 m. B) At 3 days, -SMA-positive cells (arrows) in the fibrin surrounding the AVL. Scale bar  50 m.
C) At 7 days, numerous -SMA-positive cells in the proliferative zone (P) and mature connective tissue zone (M). Scale bar 
50 m. D) At 10 days, -SMA-positive cells in arteriole walls (thick arrow), surrounding capillaries (double arrow), and as
individual cells (arrowhead). Scale bar  50 m. E) At 21 days, venules (arrows) labeled with -SMA. Scale bar  50 m. F) At
112 days there is a reduction in -SMA labeling intensity in arterioles (arrow) and interstitium. Scale bar 50 m. G) No desmin
labeling in an arteriole wall (arrow) in negative control tissue from a 10 day AVL construct. Scale bar  20 m. H) At 7 days,
isolated individual cells (arrow) and I) medial SMCs in small blood vessels (arrow) labeled with desmin. Scale bar: H) 100 m;
I)  50 m. J) At 10 days, arteriole wall SMCs (arrows) labeling with desmin. Scale bar  50 m. K) At 21 days, reduction in
desmin labeling intensity in arteriole walls (arrows). Scale bar  50 m.
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scope. Capillary sprouts were seen extending from the
femoral vein at 7 days, with profuse sprouting from the
vein at day 10 (Fig. 2I, J). At day 10 a few arteriolar-like
sprouts from the recipient artery were noted (Fig. 2I).
More extensive sprouting was observed at 14 days from
both the femoral artery (Fig. 2K, L) and vein, but not
from the vein graft. Blood vessel sprouts were not
evident from the vein graft at any time examined (Fig.
2I, K). However, both the artery- and vein-derived
sprouts grew in the direction of the vein graft and
coursed along its abluminal surface.
TEM identification of early blood vessel growth
Several morphologies of new capillary formation were
observed in 7 day AVL constructs. A distinctive feature
were numerous large elongated or “tear-drop”-shaped
cells having an immature mesenchymal appearance,
presumed to be endothelial precursors. These cells had
a large open oval nucleus with a narrow rim of chro-
matin clumping and cytoplasm filled with granular
endoplasmic reticulum. These large cells often ap-
peared in groups frequently aligned parallel to one
another (Fig. 5A). The majority did not appear to make
cell-cell contact, although occasional contact and slight
overlapping was observed. Individual cells containing
extremely dilated endoplasmic reticulum, giving the
cell a vacuolated appearance (Fig. 5B)—possibly indi-
cating lumen formation—were also present. In addi-
tion, definitive solid capillary sprouts were seen (Fig.
5C). Slightly later stages of sprout development (Fig.
5D), where the shape and alignment of two opposite
ECs appeared complementary (suggesting that the two
might have formed a solid cord and then separated to
form a lumen) were evident. In capillary sprouts the
capillary endothelial cell was thick (Fig. 5C), containing
much granular endoplasmic reticulum and many free
ribosomes. The nuclear appearance was becoming
more elongated and irregular in outline, with denser
and more prominent peripheral clumping.
Pericytes were observed on the abluminal surface of
the capillary (Fig. 5D). Their morphology was not
dissimilar to that of the endothelium; however, a con-
spicuous feature were numerous free ribosomes within
their cytoplasm. Before their alignment to the ablumi-
nal surface of a capillary, it was impossible to morpho-
logically distinguish individual pericytes from ECs.
Hypoxia studies
Positive control liver tissue in animals receiving hy-
poxyprobe-1 demonstrated labeling in many liver hepa-
tocytes (Fig. 6A). Negative control tissue did not dem-
onstrate labeling (Fig. 6B, C). Hypoxic inflammatory
Figure 4. VEGFR-2 labeling. A) VEGFR-2 labeling is absent in negative control tissue in a 7 day construct. Scale bar  50 m.
B) At 3 days, isolated VEGFR-2-positive cells (arrows) in the fibrin matrix surround the AVL femoral vein. Scale bar  50 m.
C) At 7 days, VEGFR-2 labeling in capillary endothelium (arrows) in the proliferative zone. Scale bar  50 m. D) Femoral vein
at 7 days, including large VEGFR-2-positive cells (arrow) in the vein wall outside the endothelial layer. The VEGFR-2-positive cell
indicated is dividing. Scale bar  50 m. E) At 10 days, VEGFR-2 labeling in capillaries (arrows). Scale bar  50 m. F) At 28
days, blood vessels (arrows) no longer label with VEGFR-2. Scale bar  50 m.
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cells (predominantly neutrophils and monocytes) and
myofibroblasts were observed throughout the fibrin
matrix at 3 days (Fig. 6D). Hypoxyprobe-1 labeling was
most intense and widespread at 7 days (Fig. 6E),
occurring within capillary endothelium and interstitial
cells throughout the cuff of new connective tissue
formed around the AVL. Labeling was most intense at
the front of the migrating proliferative zone whereas
mature tissue adjacent to the AVL did not label (Fig.
6E, F), indicating adequate oxygen perfusion to this
new tissue. From 14 days, as the proliferative zone
gradually disappeared, hyproxyprobe-1 labeling dimin-
ished (Fig. 6G) and was absent from 28 days onward.
Morphometric determination of connective tissue
components and vascular volume density
At 3 days the percent volume of fibrin was 75.18 (4.0)
%, being significantly higher than all subsequent time
points (Fig. 7A). Fibrin percent volume rapidly de-
clined to 22% (2.38%) at 14 days and was almost
undetectable at 112 days (0.190.19%). The connec-
tive tissue component showed the opposite trend, be-
ing 	10% (6.142.91%) at 3 days, but increased
significantly (P	0.001) to 57.43% (3.57%) at 14 days.
This level was maintained over the subsequent time
frame studied (Fig. 7A).
Blood vessel percent volume was observed to increase
from 	1% at 3 days to 10% at 10 days, and remained
Figure 5. TEM of new blood vessel formation in 7 day AVL
constructs. A) Two large tear drop-shaped mesenchymal cells
containing an undifferentiated nucleus (N) and large
amounts of endoplasmic reticulum (arrow). Scale bar  1
m. B) Mesenchymal cells containing extremely dilated vacu-
oles (asterisk), possibly indicative of lumen formation. Scale
bar  1 m. C) A solid capillary sprout with a slight widening
of the intercellular space (arrow) indicating early lumen
formation. E: endothelial cells. Scale bar  1 m. D) A later
stage of sprout development with a lumen (L) apparent
between endothelial cells (E). The opposite sides of the
endothelial lining appear to fit together (asterisks), suggest-
ing they were previously interlocked as a solid sprout. P:
pericyte. Scale bar  1 m.
Figure 6. Demonstration of hypoxia in AVL constructs with hypoxyprobe-1 labeling. A) Positive control liver hepatocytes. Scale
bar  100 m. B) Absence of hypoxyprobe-1 labeling in negative control liver tissue from an animal that did not receive
hypoxyprobe-1. Scale bar 100 m. C) Negative control tissue (without application of primary antibody) from a 7 day construct
demonstrating no labeling. Scale bar  100 m. D) At 3 days, individual cells (arrows) positively label for hypoxyprobe-1 in the
fibrin matrix adjacent to the AVL. Scale bar  100 m. E) At 7 days; F) at 10 days, positive labeling in a cuff of tissue
corresponding to the proliferative zone (P). New capillaries (arrows) and interstitial cells label. The mature connective tissue
adjacent to the AVL does not label (asterisks). Scale bars  100 m. G) At 14 days the AVL and proliferative zone (P) do not
label, but individual macrophages still label (arrow). Scale bar  100 m.
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at approximately this value for up to 112 days. It was
considered more appropriate to determine percent
vascular volume in relation to the new connective tissue
produced in the construct (see below) rather than the
entire construct, as the latter includes clearly avascular
zones such as the fibrin matrix.
Vascular volume density was determined as a percent-
age of connective tissue in AVL constructs over time (Fig.
7B). Vascularization of the chamber construct starts be-
tween 3 and 7 days, and increased significantly to peak at
10 days (23.203.14%, P	0.001, day 3 vs. day 10). Vascu-
lar volume percent declined slightly after 10 days but was
maintained at 112 days at 13.73% (2.14%).
Proliferation and apoptotic cell studies
At 3 days, a few proliferating cells were observed in the
fibrin matrix but not in the EC or SMCs of the AVL.
From 7 days onward, Ki67-positive cells included pre-
dominantly pericytes, ECs (Fig. 8B), and myofibroblasts
in the new connective tissue and occasionally in the
femoral vein and artery wall. A significantly increased
and maximal proliferative cell number was observed at
7 days (114.617.3 cells/mm2, P	0.001, 7 days vs. 3
days) (Fig. 8C).
The first apoptotic cells in the chamber were spindle-
shaped cells seen at the periphery of the migrating
Figure 7. Percent volume of construct tissue
components. A) Percent volume of construct
tissues: fibrin, connective tissue, blood vessels,
and AVL from 3 to 112 days. #Percent volume of
fibrin at 3 days is significantly higher than at all
subsequent time points (7 days, P	0.05; 10, 14,
21, 28, 42, 56, and 112 days, P	0.001). *Percent
volume of connective tissue at 3 days is signifi-
cantly less than that at all subsequent time
points (7 days, P	0.05; 10 days, P	0.01; 14, 21,
28, 42, 56, and 112 days, P	0.001). B) Percent
vascular volume of new blood vessels in connec-
tive tissue from 3 to 112 days. *,#,
Percent
vascular volume was significantly higher at
7–112 days compared with 3 day AVL constructs
(*7, 14, 21,112 days, P	0.05; #28, 56 days,
P	0.01; 
10, 42 days, P	0.001).
Figure 8. Cell proliferation and apoptosis in
AVL constructs. A) Positive control tissue dem-
onstrating Ki67 labeling in the small intestinal
crypts (arrows). Scale bar 50 m. B) At 7 days,
Ki67 labeling in the endothelium (arrow) and
in a pericyte (arrowhead) wrapped around the
endothelial abluminal surface. Scale bar  2
m. C) Cell proliferation (proliferating cells/
mm2) in AVL constructs from 3 to 112 days.
*Cell proliferation was significantly higher at 7
days compared with 3 (P	0.001), 10 (P	0.01),
and 14, 21, 28, 42, 56, and 112 day groups
(P	0.001). D) Positive control: labeling of apo-
ptotic cells in rat lymph node (arrow). Scale
bar  10 m. E) Detachment of an apoptotic
EC (arrow) from the underlying capillary base-
ment membrane in a 112 day construct. Apo-
ptotic cells are present outside the blood vessel
and include pericytes (white arrowhead) and
macrophages (white asterisk). Scale bar  2
m. F) Cell apoptosis (apoptotic cells/mm2) in
AVL constructs from 3 to 112 days. Macro-
phages containing apoptotic bodies were ex-
cluded from the counts. The number of apo-
ptotic cells/mm2 was significantly higher at 56
and 112 days compared with the 3, 7, 10,14
(P	0.001) and the 21 day group (P	0.01).
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tissue at 7 days. The first apoptotic blood vessels were
observed at 21 days, although these were isolated
events. At later times apoptotic cells included fibro-
blasts, macrophages, occasional pericytes, and capillary
ECs (Fig. 8E). Capillary apoptosis was accompanied by
arteriolar apoptosis with SMCs/pericytes labeling with
TUNEL. The number of apoptotic cells/mm2 in-
creased over time and was greatest at 112 days
(31.53.4 cells/mm2, P	0.001, 112 days vs. 3, 7, 10,
and 14 days (Fig. 8F).
DISCUSSION
Vascularization in experimental tissue engineering had
not been previously examined in detail. Little attempt
has been made to characterize extrinsic vascular in-
growth and no medium or long-term studies have been
published that examine vascular remodeling in engi-
neered constructs. In the study reported here, the
development, maturation, and remodeling of vascula-
ture and connective tissue in an intrinsically vascular-
ized (28) tissue engineering model, based on growth of
tissue from a macrovascular arteriovenous loop in-
serted into a space and protected by chamber walls,
were investigated for up to 112 days.
The spontaneous vascular growth in the AVL con-
struct was preceded by fibrin exudation from the AVL,
which filled the empty chamber. Fibrin has been ac-
knowledged as being proangiogenic (29); in this model
it also acts as a natural provisional matrix for develop-
ment of a new microcirculatory network.
Intense early angiogenesis from the AVL accompa-
nied by the migration of myofibroblasts into the fibrin
matrix was observed. At 10 days the percent vascular
volume density of new tissue was 23.20  3.14%. This is
a surprisingly high level compared with angiogenesis
observed during primary intention incisional skin
wound healing, where the maximal percent vascular
volume at 7 days was 15.83  1.10% (23). What
stimulates AVL angiogenesis is unclear; however, the
identification of hypoxyprobe-1 labeling at 3 days in the
absence of any angiogenic vessel formation off the AVL
and before maximal angiogenesis at 10 days suggests
that hypoxia may be a major driving factor (30). The
presence of a proangiogenic fibrin matrix (29), mech-
anoreceptive forces acting when the AVL is placed in a
large empty chamber space (31, 32), and shear stress
(33) within the AVL (34) are likely to positively influ-
ence the angiogenic response from the AVL.
The highest number of proliferating cells, which
included endothelial, pericyte, and myofibroblast pop-
ulations in the construct, was observed at 7 days in the
presence of a hypoxic environment, suggesting that
hypoxia is a stimulant of cellular and vessel prolifera-
tion in the AVL construct. The peak of proliferation
preceded the peak of vascular volume, indicating that
the new vessels could develop in response to the
increased cellular population present in the construct
matrix.
Both histological and vascular cast observations sug-
gest that capillaries first appear around the vein portion
of the AVL between 3 and 7 days, whereas arterioles
appear around the artery portion of the AVL between 7
and 10 days (Fig. 9). Vascular casts also demonstrated
no sprouting from the vein graft segment of the loop in
the first 14 days, when overall vascular growth was
maximal. A clear directional pull of both venous and
arterial sprouts along the axis of the vein graft (ob-
served for up to 14 days) may be related to a more
hypoxic environment around the graft that does not
generate any new vessels. Together with the previous
findings that blind ending ligated arteriovenous vascu-
lar pedicles without an intervening vein graft resulted
in sprouting of a significant vascular plexus in vivo (34),
Figure 9. Graphic summarizing the events in
the AVL chamber resulting in the production
of a complex microcirculatory network.
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these results suggest that the vein graft is not necessary
for the formation of a microcirculatory plexus from the
AVL, and indicate that reduced donor site scarring and
quicker operative times could be achieved by using a
ligated pedicle or “off the shelf” synthetic or bioengi-
neered vascular grafts.
Light microscopic, immunohistochemical, and TEM
observations suggest that undifferentiated cells in and
adjacent to the recipient vein wall migrate into the
fibrin matrix in aligned groupings of cells often appear-
ing to be moving parallel to one another (Fig. 9). The
close proximity of these cells to one another suggests
that they eventually achieve cell-to-cell contact, forming
a sprout. This method of capillary formation has been
described (35). In addition, solid endothelial sprouts
without a lumen or with a narrow lumen were observed,
suggesting lumen formation by separation of individual
ECs from one another (35).
In addition to the capillary network, the first arte-
rioles were initially seen around the recipient artery
relatively early (between 7 and 10 days), as observed
both in vascular casts and histologically. Venules were
apparent at 14–21 days. The AVL construct therefore
forms an extensive arteriole-capillary-venule network,
peaking in percent vascular volume at 10 days and
continuing to mature thereafter. This vascular network,
though undergoing remodeling, remains intact at 112
days.
The presence of apoptotic cells within the new tissue
rose gradually from 14 days to reach a maximal num-
ber/mm2 at 112 days, suggesting that the actual peak in
apoptosis could be beyond this time point. When
compared with the blood vessel remodeling in primary
intention incisional skin wounds (23), which peaks at
21 days, remodeling in the AVL construct occurs much
later. Remodeling via apoptosis was evident in capillary
ECs and in pericytes and SMCs/pericytes around arte-
rioles, but this remodeling did not cause a significant
loss of microcirculation as measured by percent vascu-
lar volume. The increase in cell apoptosis from 14 days
occurred in the absence of detectable hypoxia, thus
excluding the possibility that hypoxia could activate
cellular apoptosis (36) in this model. Whether micro-
circulatory remodeling occurs in response to changes
in growth factor concentration, remodeling of the
ECM, loss of interstitial connective tissue cells (37, 38),
and/or is a consequence of lack of functional demand
on the formed vascular network remains to be deter-
mined.
The AVL construct presents a temporal window for
cellular manipulation between the angiogenic growth
phase and commencement of remodeling of the
formed tissue. Cell proliferation and angiogenesis are
maximal at 7 and 10 days, respectively, suggesting that
at this time the AVL construct is most suitable for tissue
engineering-directed manipulation. In particular, this
time presents an ideal opportunity for the seeding of
stem or progenitor cells that could proliferate, differ-
entiate, and expand in the chamber space to develop
specific tissue types while simultaneously being nour-
ished by the developing microcirculation.
Placement of a macrovascular AVL in an empty
polycarbonate chamber leads to the spontaneous gen-
eration of a microcirculatory network. It can be con-
cluded that:
1) Angiogenic and connective tissue growth in the
AVL chamber model occurs under hypoxic conditions,
whereas the remodeling phase does not occur under
hypoxic conditions. 2) A natural transient ECM, a fibrin
exudate, supports early radial blood vessel growth from
the AVL. 3) Adult tissue growth normally is stimulated
by injury, functional demand, or endocrine stimulus. In
the rigid noncollapsible chamber, tissue growth is
amplified by the presence of a large, permanent, de-
fined tissue space that protects the fibrin matrix, which
under normal conditions would be dissipated into
adjacent tissues. Within this protected space, new tis-
sues and vasculature can expand. The provision of
space for growth in this model appears highly signifi-
cant and represents a new paradigm of vascularized
tissue growth. 4) A temporal window exists between 7
and 10 days appropriate for seeding exogenous stem or
progenitor cells to achieve development of specific
tissues in the presence of concurrent active vasculariza-
tion. 5) Vascular and cellular remodeling of the con-
struct tissue through apoptosis commences 14–21
days and reaches a peak at 112 days. Analysis of the
tissue weight, volume, percent vascular volume, and
general histological assessment indicate that this re-
modeling is not detrimental to the viability of the tissue
construct.
The AVL chamber model with its intense early vas-
cularization has enormous potential to allow manipu-
lation of the chamber constituents so as to direct
growth to specific tissue or organ end points. The
model therefore has direct clinical application in grow-
ing new tissues and organs for reconstructive surgery,
organ, and tissue replacement.
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